Table 1 Summary of ICI metagenome studies

From: Gut microbial structural variation associates with immune checkpoint inhibitor response

Study

Study name utilized in this study

Accession number

N#

N*

Cancer type included

Treatment

Clinical outcomes

Country$

Frankel et al., Neoplasia 2017

FrankelAE_2017

PRJNA397906

39

39

Melanoma

CTLA4/PD-1 blockade

Response

USA

McCulloch et al.,Nature Medicine. 2022

McCullochJA_2022

PRJNA762360

62

62

Melanoma

PD-1 blockade

Response/irAEs/OS/PFS

USA

Spencer et al.,Science 2021

SpencerCN_2021

PRJNA770295

167

155

Melanoma

PD-1 blockade

Response/PFS

USA

Peters et al., Genome Medicine 2019

PetersBA_2019

PRJNA541981

48

23

Melanoma

CTLA4/PD-1 blockade

OS/PFS

USA

Lee et al.Nature Medcine.2022

LeeKA_2022

PRJEB43119

164

162

Melanoma

CTLA4/PD-1 blockade

Response/PFS12

UK

Routy et al., Science 2018

RoutyB_2018

PRJEB22863

219

219

NSCLC; RCC

PD-1 blockade

Response

France

Derosa et al.Nature Medcine.2022

DerosaL_2022

PRJNA751792

338

336

NSCLC

PD-1 blockade

Response/OS

France/Canada

  1. OS overall survival, PFS progression-free survival, NSCLC non-small-cell lung cancer, RCC renal cell carcinoma, PFS12 whether PFS longer than 12 months, irAEs immune-related adverse events.
  2. # Sample size in the original paper.
  3. *Samples collected pretreated with ICIs and with matched clinical and metagenome data available which utilized in this study, the filter process listed in Fig. S1.
  4. $ The country in which the study was recruited.
Back to article page